Biotricity Inc. (Biotricity) has signed an agreement with a leading group ‎purchasing organization (“GPO”) for national distribution of its cardiac monitoring solutions, Bioflux® and Biotres^TM.  Both Bioflux and Biotres are designed for cardiologists to diagnose and monitor their patients remotely. GPO’s are entities comprised of businesses organized to purchase materials or supplies from vendors in larger volumes to gain efficiency. In this case, the GPO is comprised of hundreds of small, independent US hospitals, private ‎clinics, and medical offices that purchase medical devices and supplies at scale.

Biotricity Inc. (Biotricity) today announced that it made a 510(k) submission to the U.S. Food and Drug Administration (FDA) for a new form factor of its Biotres Cardiac Monitoring Device, a three lead device for ECG and arrhythmia monitoring that is intended for lower risk patients.